Where Can You Report Your Adverse Drug Reactions Or Adverse Events Following Immunization

اين يمكنك التبليغ عن الاحداث الجانية للأدوية واللقاحات

Where Can You Report your Adverse Drug Reactions or Adverse Events Following Immunization

This section provides a comprehensive overview of the procedures and tools available to Healthcare Professionals, Market Authorization Holders and the General Public to report adverse events associated with medicinal products and vaccines in Lebanon.

How to report

You can send the case reports using the following tools:

For Healthcare Professionals and the Public

The Lebanese National Pharmacovigilance Program has adapted two user-friendly tools: one for Adverse Drug Reactions (Vigimobile e-Reporting e-Form) and another for reporting Adverse Events Following Immunization (Vigimobile e-Form). Both tools may be accessed by healthcare professionals and the general public.

The VigiMobile e-Form and e-Reporting e-Form:

The VigiMobile e-Form and e-Reporting e-Form are the latest tools launched in January 2025 by the Lebanese National Pharmacovigilance Program. These digital platforms were introduced to enhance the reporting process, with the e-Reporting e-Form designed for Adverse Drug Reactions (ADRs) and the VigiMobile e-Form specifically for Adverse Events Following Immunization (AEFIs).

How to Download on Android Phones

Scan the QR Code by pressing the link
Click the three dots in the top-right corner
Choose Install app
VigiMobile e-Form/e-Reporting e-Form now appears as an app

How to Download on Apple IOS Phones

Scan the QR Code by pressing the link
Click on the share button
Add VigiMobile to the home screen
VigiMobile e-Form/e-Reporting e-Form now appears as an app

How to Download on Windows

Press on the link
Install from the Browser menu
VigiMobile e-Form/e-Reporting e-Form is now installed

Scan QR Codes to Report:

ADRs Following Medication Use	AEFIs Following Vaccine Use

Or use the following link: LNPVP: e-Reporting eForm	Or use the following link: LNPVP: VigiMobile eForm

Direct Contact with the Lebanese National Pharmacovigilance Program:

You may contact the Lebanese National Pharmacovigilance Program through:

Email Address:

pv@moph.gov.lb, pv.moph@gmail.com

Phone number of the Quality Assurance of Pharmaceutical Products Program: 01-830254

For Market Authorization Holders:

Based on the Ministerial Resolution MR #181 issued in 2021, MAHs should adhere to the internationally agreed ICH guidelines and standards and send the reports in XML format as specified in ICH E2B (R2 or R3) guidelines

(https://www.moph.gov.lb/userfiles/files/Quality%26Safety/PharmacovigilanceSystemInLebanon/Karar%20181-2021.pdf).

All XML files should be sent to the following emails: pv@moph.gov.lb, and pv.moph@gmail.com.

As for what to report or report type, you can refer to Module VI:
https://moph.gov.lb/en/Pages/4/44742/pharmacovigilance-system-lebanon#/en/view/70479/lebanese-guideline-on-good-pharmacovigilance-practices-lgvp-

...

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
J01DD01	STOPAREN	G	Cefotaxime (sodium) - 1g	1g	Injectable lyophilised powder for solution+diluent	213,671 L.L
R01AD09	SINOCORT METERED DOSE	G	Mometasone furoate - 0.05%	0.05%	Spray, suspension	419,279 L.L
G04CB01	STERIFINE 5	G	Finasteride - 5mg	5mg	Tablet, film coated	733,354 L.L
L04AA10	SIROMUNE	G	Sirolimus - 1mg	1mg	Tablet, film coated	18,729,193 L.L
A02BX02	SUCRATE GEL	G	Sucralfate - 1g	1g	Gel	636,981 L.L
L01EX01	SOVIDEX	G	Sunitinib maleate - 12.5mg	12.5mg	Capsule	36,042,560 L.L
G04CB01	STERIBO	G	Finasteride - 1mg	1mg	Tablet, film coated	2,636,619 L.L
L01EX01	SUNITINIB AQVIDA	G	Sunitinib maleate - 12.5mg	12.5mg	Capsule, hard	41,692,397 L.L
L01EX01	SOVIDEX	G	Sunitinib maleate - 25mg	25mg	Capsule	64,804,314 L.L
B05XA03	SERUFLEX SODIUM CHLORIDE 0.9% INJECTION USP	G	Sodium chloride - 0.9%	0.9%	Injectable solution	156,288 L.L
L01EX01	SOVIDEX	G	Sunitinib maleate - 50mg	50mg	Capsule	118,623,323 L.L
N06AB06	SERTINE	G	Sertraline HCl - 50mg	50mg	Tablet, scored	520,899 L.L
B05XA03	SERUFLEX SODIUM CHLORIDE 0.9% INJECTION USP	G	Sodium chloride - 0.9%	0.9%	Injectable solution	165,482 L.L
J01RA	SPIRAGYL	G	Metronidazole - 125mg, Spiramycin - 750,000IU		Tablet, scored	474,824 L.L
L01EX01	SUNITINIB AQVIDA	G	Sunitinib maleate - 50mg	50mg	Capsule, hard	151,885,541 L.L
N06AB06	SERTINE	G	Sertraline HCl - 50mg	50mg	Tablet	714,156 L.L
B05XA03	SERUFLEX SODIUM CHLORIDE 0.9% INJECTION, USP	G	Sodium chloride - 0.9%	0.9%	Injectable solution	176,974 L.L
N06AB06	SERTRA TAD	G	Sertraline HCl - 50mg	50mg	Tablet, film coated	689,391 L.L
B05XA03	SERUFLEX SODIUM CHLORIDE 0.9% INJECTION, USP	G	Sodium chloride - 0.9%	0.9%	Injectable solution	163,184 L.L
J01RA	SPIRAGYL FORTE	G	Metronidazole - 250mg, Spiramycin - 1,500,000IU		Tablet, scored	474,824 L.L
N06AB06	SERTRALINE BIOGARAN	G	Sertraline HCl - 50mg	50mg	Capsule	520,067 L.L
B05XA03	SERUFLEX SODIUM CHLORIDE 0.9% INJECTION, USP	G	Sodium chloride - 0.9%	0.9%	Injectable solution	156,288 L.L
N06AB06	SOLOTIK	G	Sertraline HCl - 50mg	50mg	Tablet, film coated	428,686 L.L
A03AA04	SPASMINE (Mebeverine HCl 200mg SR)	G	Mebeverine HCl - 200mg	200mg	Capsule, slow release	712,876 L.L
B05XA03	SODIUM CHLORIDE	G	Sodium chloride - 0.9%	0.9%	Injectable solution	4,143,943 L.L
L04AA27	SCLEMOD	G	Fingolimod Hydrochloride - 0.5mg	0.5mg	Capsule	18,264,981 L.L
M01AE03	SOLKET	G	Ketoprofen Lysine salt - 80mg	80mg	Powder for solution	636,981 L.L
B05XA03	SODIUM CHLORIDE	G	Sodium chloride - 0.9%	0.9%	Injectable solution	3,985,356 L.L
L04AA27	SCLEMOD	G	Fingolimod Hydrochloride - 0.5mg	0.5mg	Capsule	17,079,643 L.L
M01AE03	SOLKET INFLAMMATION AND PAIN	G	Ketoprofen Lysine salt - 0.16%	0.16%	Spray	946,065 L.L

...